BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 33747636)

  • 1. Efficacy of immune-checkpoint inhibitors in PD-L1 selected or unselected patients vs. control group in patients with advanced or metastatic urothelial carcinoma.
    Guo L; Wang X; Wang S; Hua L; Song N; Hu B; Tong Z
    Oncoimmunology; 2021 Mar; 10(1):1887551. PubMed ID: 33747636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analysis.
    Yu Y; Jin X; Zhu X; Xu Y; Si W; Zhao J
    Front Immunol; 2023; 14():1206689. PubMed ID: 37377959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis.
    Khan M; Du K; Ai M; Wang B; Lin J; Ren A; Chen C; Huang Z; Qiu W; Yuan Y; Tian Y
    Front Immunol; 2023; 14():1060308. PubMed ID: 36949944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line treatment options for advanced non-small cell lung cancer patients with PD-L1 ≥ 50%: a systematic review and network meta-analysis.
    He M; Zheng T; Zhang X; Peng Y; Jiang X; Huang Y; Tan B; Yang Z
    Cancer Immunol Immunother; 2022 Jun; 71(6):1345-1355. PubMed ID: 34657171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Programmed Death-1/Programmed Death-Ligand 1 Inhibitor for Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
    Liao PF; Wang PY; Peng TR
    Curr Oncol; 2023 Nov; 30(11):9940-9952. PubMed ID: 37999142
    [No Abstract]   [Full Text] [Related]  

  • 6. Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis.
    Qian X; Chen H; Tao Y
    Front Immunol; 2023; 14():1146898. PubMed ID: 37063822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical benefits of PD-1 inhibitors in specific subgroups of patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of phase 3 randomized clinical trials.
    Lu Y; Wang W; Wang F
    Front Immunol; 2023; 14():1171671. PubMed ID: 37205107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Performance Status on Oncologic Outcomes in Patients with Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitor: A Systematic Review and Meta-analysis.
    Kawada T; Yanagisawa T; Mostafaei H; Sari Motlagh R; Quhal F; Rajwa P; Laukhtina E; von Deimling M; Bianchi A; Majdoub M; Pallauf M; Pradere B; Teoh JY; Karakiewicz PI; Araki M; Shariat SF
    Eur Urol Focus; 2023 Mar; 9(2):264-274. PubMed ID: 36774273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reconstruction of unreported subgroup survival data with PD-L1-low expression in advanced/metastatic triple-negative breast cancer using innovative KMSubtraction workflow.
    Li Y; Liang X; Li H; Chen X
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38212119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinico-characteristics of patients which correlated with preferable treatment outcomes in immunotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis.
    Wang Y; Lau W; Li Y; Tian Y; Lei Y; Wang J; Xia F
    Int J Surg; 2023 Nov; 109(11):3590-3601. PubMed ID: 37598406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of anti-PD-1/PD-L1 in treatment of glioma: a single-arm meta-analysis.
    Zeng YF; Wei XY; Guo QH; Chen SY; Deng S; Liu ZZ; Gong ZC; Zeng WJ
    Front Immunol; 2023; 14():1168244. PubMed ID: 37122727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of immune checkpoint inhibitors therapy versus chemotherapy in the treatment of advanced and metastatic urothelial carcinoma: a meta-analysis.
    Huang G; Xiong H; Li S; Zhu Y; Liu H
    J Cancer Res Clin Oncol; 2024 Jan; 150(1):5. PubMed ID: 38170235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of immune-checkpoint inhibitors plus chemotherapy versus chemotherapy for non-small cell lung cancer: An updated systematic review and meta-analysis.
    Kang J; Zhang J; Tian Z; Xu Y; Li J; Li M
    PLoS One; 2024; 19(2):e0276318. PubMed ID: 38319920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis.
    Bartoletti M; Montico M; Lorusso D; Mazzeo R; Oaknin A; Musacchio L; Scambia G; Puglisi F; Pignata S
    Cancer Treat Rev; 2024 Apr; 125():102701. PubMed ID: 38422895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of PD-1 inhibitors in recurrent or metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens: a systematic review and meta-analysis.
    Luo J; Xiao W; Hua F; Cao Y; Wang D; Wang X
    BMC Cancer; 2023 Nov; 23(1):1172. PubMed ID: 38037076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of PD-1 Inhibitors in First-Line Treatment for Advanced Gastroesophageal Junction and Gastric Cancer by Subgroups: A Systematic Review and Meta-Analysis.
    Fei S; Lu Y; Chen J; Qi J; Wu W; Wang B; Han Y; Wang K; Han X; Zhou H; Wang J; Chen J
    Chemotherapy; 2023; 68(4):197-209. PubMed ID: 37331333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations of DNA damage response genes correlate with response and overall survival in anti-PD-1/PD-L1-treated advanced urothelial cancer.
    Joshi M; Grivas P; Mortazavi A; Monk P; Clinton SK; Sue-Ann Woo M; Holder SL; Drabick JJ; Yin M
    Cancer Med; 2020 Dec; 9(24):9365-9372. PubMed ID: 33098265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers and factors in small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
    Li LL; Yu CF; Xie HT; Chen Z; Jia BH; Xie FY; Cai YF; Xue P; Zhu SJ
    Cancer Med; 2023 May; 12(10):11211-11233. PubMed ID: 37161541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of blood-based PD-L1 analysis in patients with non-small cell lung cancer undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis.
    Cui Q; Li W; Wang D; Wang S; Yu J
    World J Surg Oncol; 2023 Oct; 21(1):318. PubMed ID: 37821941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the safety and efficacy of combination chemotherapy and PD-1/PD-L1 inhibitor treatment of breast cancer: A meta-analysis.
    Qian D; Xu Y; Wu Y; Qiu J; Hong W; Meng X
    Chin Med J (Engl); 2023 Jul; 136(14):1663-1670. PubMed ID: 37279392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.